<DOC>
	<DOCNO>NCT00885963</DOCNO>
	<brief_summary>This open label , single arm , phase II study evaluate safety efficacy oral sapacitabine administer twice daily 5 consecutive day every week 2 week follow 7-day rest patient one prior chemotherapy regimen advance Non-Small Cell Lung Cancer ( NSCLC ) .</brief_summary>
	<brief_title>A Study Oral Sapacitabine Patients With Previously Treated Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically cytologically confirm recurrent NSCLC Age 18 year old Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Measurable disease accord RECIST Had 1 prior chemotherapy regimen metastatic recurrent disease ; patient receive one prior chemotherapy regimen may participate Part A study . Adequate bone marrow function Adequate renal function Adequate liver function At least 3 week prior systemic treatment include investigational anticancer therapy ; least 7 day prior radiation therapy ; recover prior toxicity At least 3 week major surgery Patient must able swallow capsule Agree practice effective contraception entire study period one month discontinue study unless documentation infertility exists . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately Ability understand willingness sign inform consent form NSCLC histology contains component small cell lung cancer Previously untreated CNS metastasis progressive CNS metastasis document MRI scan perform 4 week longer last treatment CNS metastasis Currently receive radiotherapy , biological therapy , investigational agent Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Cancer NSCLC treat chemotherapy biological therapy past 5 year exception adequately treat situ cervical cancer , basal squamous cell skin cancer ; patient receive hormonal therapy neoadjuvant adjuvant set past 5 year may participate study Pregnant lactate woman Known HIVpositive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>